Actively Recruiting
Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
Led by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Updated on 2025-09-08
350
Participants Needed
1
Research Sites
125 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The trial consists of Stage 1 (including dose escalation and dose expansion) and Stage 2 (proof-of-concept study). Among them, Stage 2 adopts a randomized, controlled, open-label, and multicenter design.
CONDITIONS
Official Title
Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to understand and voluntarily sign the written informed consent form
- Male or female patients aged 18 years or older
- Diagnosed with advanced solid tumors by pathology or cytology
- Her-2 expression status known; if positive, previous anti-Her-2 therapy received
- MET overexpression and/or amplification confirmed by central laboratory in tumor tissue or blood samples
- Presence of measurable or evaluable lesions according to RECIST v1.1
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
- Expected survival time of at least 3 months
- Adequate major organ and bone marrow function
You will not qualify if you...
- Prior treatment with targeted MET drugs
- Previous treatment including docetaxel
- Presence of meningeal metastases, spinal cord compression, or symptomatic/progressive brain metastases
- Known allergy or intolerance to study drugs or their components
- Unrecovered adverse events from prior anti-tumor treatments above Grade 1 (except certain alopecia)
- Severe or uncontrolled co-existing diseases preventing participation
- Lactating or pregnant women; positive pregnancy test within 7 days before enrollment
- Women of childbearing potential not using effective contraception during and 6 months after trial
- Male or female patients of childbearing potential refusing effective contraception during and 6 months after trial
- Unwillingness or inability to comply with study procedures or judged unsuitable by investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Actively Recruiting
Research Team
C
Clinical Trials Information Group officer
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here